Chronic Dantrolene Treatment Does Not Affect Hypertension, but Attenuates Sympathetic Stimulation Enhanced Atrial Fibrillation Inducibility in SHR

Am J Hypertens. 2020 Apr 29;33(5):407-413. doi: 10.1093/ajh/hpaa021.

Abstract

Background: Ryanodine receptor (RyR) dysfunction in skeletal muscle (RyR1) leads to malignant hyperthermia, and in cardiac muscle (RyR2) triggers cardiac arrhythmias. We hypothesized that RyR dysfunction in vascular smooth muscle could increase vascular resistance and hypertension, and may contribute to increased atrial fibrillation (AF) in hypertension. Thus, stabilizing RyR function with chronic dantrolene treatment may attenuate hypertension and AF inducibility in spontaneously hypertensive rats (SHR).

Methods: Male SHR (16 weeks old) were randomized into vehicle- (n = 10) and dantrolene-treated (10 mg/kg/day, n = 10) groups for 4 weeks. Wistar Kyoto (WKY, n = 11) rats served as controls. Blood pressures (BP) were monitored before and during the 4-week treatment. After 4-week treatment, direct BP, echocardiography, and hemodynamics were recorded. AF inducibility tests were performed in vivo at baseline and repeated under sympathetic stimulation (SS).

Results: Compared with WKY, SHR had significantly higher BP throughout the experimental period. Dantrolene treatment had no effect on BP levels in SHR (final systolic BP 212 ± 9 mm Hg in vehicle group vs. 208 ± 16 mm Hg in dantrolene group, P > 0.05). AF inducibility was very low and not significantly different between 5-month-old WKY and SHR at baseline. However, under SS, AF inducibility and duration were significantly increased in SHR (20% in WKY vs. 60% in SHR-vehicle, P<0.05). Dantrolene treatment significantly attenuated AF inducibility under SS in SHR (60% in vehicle vs. 20% in dantrolene, P < 0.05).

Conclusions: Stabilizing RyR with chronic dantrolene treatment does not affect hypertension development in SHR. SHR has increased vulnerability to AF induction under SS, which can be attenuated with dantrolene treatment.

Keywords: atrial fibrillation; blood pressure; dantrolene; hypertension; spontaneously hypertensive rats.

MeSH terms

  • Animals
  • Anti-Arrhythmia Agents / pharmacology*
  • Atrial Fibrillation / etiology
  • Atrial Fibrillation / metabolism
  • Atrial Fibrillation / physiopathology
  • Atrial Fibrillation / prevention & control*
  • Blood Pressure*
  • Dantrolene / pharmacology*
  • Disease Models, Animal
  • Heart / innervation*
  • Heart Rate / drug effects*
  • Hypertension / complications
  • Hypertension / metabolism
  • Hypertension / physiopathology*
  • Male
  • Rats, Inbred SHR
  • Rats, Inbred WKY
  • Ryanodine Receptor Calcium Release Channel / drug effects*
  • Ryanodine Receptor Calcium Release Channel / metabolism
  • Sympathetic Nervous System / drug effects*
  • Sympathetic Nervous System / physiopathology

Substances

  • Anti-Arrhythmia Agents
  • Ryanodine Receptor Calcium Release Channel
  • Dantrolene